Cystic Fibrosis Weekly Update

Contents:

Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment
Antibiotics Make Bacteria More Resistant by Lowering Microbial Diversity in Lungs, Study Suggests

Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment

Oct 05, 2018 07:00 am | Vijaya Iyer

Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum and might be used to treat any fibrotic disease, including cystic fibrosis (CF), the company announced in a press release. This patent (No. 10,085,964) also covers lenabasum in potentially treating dermatomyositis and systemic sclerosis. Previous patents for this investigational therapy pertain to […]
The post Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment appeared first on Cystic Fibrosis News Today.

Antibiotics Make Bacteria More Resistant by Lowering Microbial Diversity in Lungs, Study Suggests

Oct 04, 2018 07:00 am | Vijaya Iyer

Antibiotics lessen the diversity of microbes in the lungs of cystic fibrosis (CF) patients, and make these people more susceptible to infections with bacteria that are highly resistant to antibiotics, researchers reported. The study “Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity” was published in the journal Heliyon. Acute […]
The post Antibiotics Make Bacteria More Resistant by Lowering Microbial Diversity in Lungs, Study Suggests appeared first on Cystic Fibrosis News Today.